BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38691888)

  • 21. Ginsenoside Ro Ameliorates High-Fat Diet-Induced Obesity and Insulin Resistance in Mice via Activation of the G Protein-Coupled Bile Acid Receptor 5 Pathway.
    Jiang LS; Li W; Zhuang TX; Yu JJ; Sun S; Ju ZC; Wang ZT; Ding LL; Yang L
    J Pharmacol Exp Ther; 2021 Jun; 377(3):441-451. PubMed ID: 33820830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TUDCA: An Agonist of the Bile Acid Receptor GPBAR1/TGR5 With Anti-Inflammatory Effects in Microglial Cells.
    Yanguas-Casás N; Barreda-Manso MA; Nieto-Sampedro M; Romero-Ramírez L
    J Cell Physiol; 2017 Aug; 232(8):2231-2245. PubMed ID: 27987324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance.
    Yan X; Li P; Tang Z; Feng B
    BMC Endocr Disord; 2017 Sep; 17(1):60. PubMed ID: 28946907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?
    Qi Y; Duan G; Wei D; Zhao C; Ma Y
    Molecules; 2022 Aug; 27(16):. PubMed ID: 36014536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
    Gertzen CG; Spomer L; Smits SH; Häussinger D; Keitel V; Gohlke H
    Eur J Med Chem; 2015 Nov; 104():57-72. PubMed ID: 26435512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Red ginseng extracts ameliorate high-fat diet-induced obesity and insulin resistance by activating the intestinal TGR5-mediated bile acids signaling pathway.
    Li W; Zhuang T; Wang Z; Wang X; Liu L; Luo Y; Wang R; Li L; Huang W; Wang Z; Yang L; Ding L
    Phytomedicine; 2023 Oct; 119():154982. PubMed ID: 37531904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice.
    Briere DA; Ruan X; Cheng CC; Siesky AM; Fitch TE; Dominguez C; Sanfeliciano SG; Montero C; Suen CS; Xu Y; Coskun T; Michael MD
    PLoS One; 2015; 10(8):e0136873. PubMed ID: 26312995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis.
    Kumar DP; Asgharpour A; Mirshahi F; Park SH; Liu S; Imai Y; Nadler JL; Grider JR; Murthy KS; Sanyal AJ
    J Biol Chem; 2016 Mar; 291(13):6626-40. PubMed ID: 26757816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TGR5 as a therapeutic target for treating obesity.
    Zhong M
    Curr Top Med Chem; 2010; 10(4):386-96. PubMed ID: 20180762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists.
    Miyata S; Kawashima Y; Sakai M; Matsubayashi M; Motoki K; Miyajima Y; Watanabe Y; Chikamatsu N; Taniguchi T; Tokuyama R
    Sci Rep; 2021 Apr; 11(1):9196. PubMed ID: 33911126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
    Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Selective TGR5 Ligands Based on the 5,6,7,8-Tetrahydro-5,5,8,8-tetramethylnaphthalene Skeleton.
    Terui R; Yanase Y; Yokoo H; Suhara Y; Makishima M; Demizu Y; Misawa T
    ChemMedChem; 2021 Feb; 16(3):458-462. PubMed ID: 32969181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perspective: TGR5 (Gpbar-1) in liver physiology and disease.
    Keitel V; Häussinger D
    Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):412-9. PubMed ID: 22521118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes.
    Duan H; Ning M; Zou Q; Ye Y; Feng Y; Zhang L; Leng Y; Shen J
    J Med Chem; 2015 Apr; 58(8):3315-28. PubMed ID: 25710631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology.
    Brønden A; Knop FK
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31630179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
    Sindhu T; Srinivasan P
    Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity.
    Münzker J; Haase N; Till A; Sucher R; Haange SB; Nemetschke L; Gnad T; Jäger E; Chen J; Riede SJ; Chakaroun R; Massier L; Kovacs P; Ost M; Rolle-Kampczyk U; Jehmlich N; Weiner J; Heiker JT; Klöting N; Seeger G; Morawski M; Keitel V; Pfeifer A; von Bergen M; Heeren J; Krügel U; Fenske WK
    Microbiome; 2022 Jun; 10(1):96. PubMed ID: 35739571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of action of the bile acid receptor TGR5 in obesity.
    Lun W; Yan Q; Guo X; Zhou M; Bai Y; He J; Cao H; Che Q; Guo J; Su Z
    Acta Pharm Sin B; 2024 Feb; 14(2):468-491. PubMed ID: 38322325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential action of TGR5 agonists on GLP-2 secretion and promotion of intestinal adaptation in a piglet short bowel model.
    Lin S; Stoll B; Robinson J; Pastor JJ; Marini JC; Ipharraguerre IR; Hartmann B; Holst JJ; Cruz S; Lau P; Olutoye O; Fang Z; Burrin DG
    Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G641-G652. PubMed ID: 30920308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes.
    Agarwal S; Sasane S; Kumar J; Deshmukh P; Bhayani H; Giri P; Giri S; Soman S; Kulkarni N; Jain M
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1849-1852. PubMed ID: 29655980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.